What Autoimmune Diseases Are Linked to Lichen Sclerosus?

People with lichen sclerosus carry autoimmune conditions at roughly three times the rate of the general population, and the linked diseases span several organ systems. A 2025 meta-analysis pooling eleven studies found the strongest associations with skin-related autoimmune diseases, particularly morphea, lichen planus, vitiligo, and alopecia areata, followed by autoimmune thyroid disease and certain gastrointestinal conditions like celiac disease and Crohn’s disease.¹ The overlap is real enough that some clinics now screen lichen sclerosus patients for thyroid antibodies and other markers as a matter of routine.

About One in Four Patients Has at Least One Autoimmune Condition

Before looking at individual diseases, the overall picture is striking. A case-control study comparing women with vulvar lichen sclerosus to matched controls found that about 28% of lichen sclerosus patients had an autoimmune disorder, compared with 9% of controls.² That gap held up across different study designs and populations. The question researchers keep circling is whether lichen sclerosus triggers other autoimmune processes, whether they share a common immune misfire, or whether both explanations are partly true. Most evidence points toward shared genetic susceptibility rather than one disease causing another, but the practical takeaway is the same: if you have lichen sclerosus, your chances of developing another autoimmune condition are meaningfully higher than average.

Skin Autoimmune Diseases Show the Strongest Links

The diseases most tightly connected to lichen sclerosus are other autoimmune skin conditions, and the strength of some of these associations is dramatic. Morphea, a form of localized scleroderma that causes hardened patches of skin, showed the highest odds in the 2025 meta-analysis. Lichen planus, vitiligo, alopecia areata, and psoriasis all showed elevated odds as well.¹

The morphea connection is especially interesting to dermatologists. Both conditions involve immune-driven changes to connective tissue, and case reports describe patients whose biopsies show features of both diseases in the same patch of skin, suggesting they may sit on a shared disease spectrum rather than being entirely separate entities.³ That overlap makes clinical sense: both involve collagen abnormalities in the dermis, both can cause skin thinning or hardening, and both respond to similar treatments.

The relationship between lichen sclerosus and vitiligo has drawn attention partly because both conditions affect skin appearance and partly because they seem to share an immune mechanism called epitope spreading. Once the immune system attacks one skin protein, the inflammatory damage can expose neighboring proteins, prompting the immune system to attack those too. Researchers studying patients with both conditions have observed this pattern, with vitiligo lesions developing alongside lichen sclerosus in characteristic body areas.⁴

Alopecia areata, the patchy hair loss condition, and psoriasis round out the dermatologic associations. Both are well-established autoimmune diseases in their own right. For patients already dealing with the itch, scarring, and discomfort of lichen sclerosus, the arrival of another skin condition can feel demoralizing. Knowing these links exist can at least speed up diagnosis and treatment rather than leaving patients wondering why new symptoms are appearing.

Autoimmune Thyroid Disease

Thyroid autoimmunity, particularly Hashimoto’s thyroiditis and Graves’ disease, has long been considered one of the most common autoimmune partners of lichen sclerosus. A study of over 500 patients found that autoimmune thyroid disease was the single most frequently associated condition, present in about 12% of the cohort, with a heavy skew toward women.⁵ The 2025 meta-analysis confirmed a significant association with autoimmune thyroid disease across pooled data.¹

The picture is not entirely clean, though. A Polish study focused specifically on girls with vulvar lichen sclerosus found no significant difference in thyroid antibody levels compared to controls, and at least one study of adult vulvar lichen sclerosus also failed to confirm the link.⁶ These negative results may reflect smaller sample sizes or different population characteristics. Still, the weight of evidence across multiple larger studies and the recent meta-analysis supports the association strongly enough that a recent multidisciplinary clinic study explicitly recommended thyroid screening for women with vulvar lichen sclerosus.⁷

Celiac Disease and Crohn’s Disease

Among gastrointestinal autoimmune conditions, celiac disease and Crohn’s disease both show up more often in people with lichen sclerosus than in the general population. The 2025 meta-analysis found a modest but significant association for both conditions.¹ A large German retrospective study reported a roughly twofold higher rate of Crohn’s disease in lichen sclerosus patients compared to the general population.⁸

Ulcerative colitis, the other major inflammatory bowel disease, did not reach significance in the meta-analysis, so the GI connection appears limited to celiac and Crohn’s. Pernicious anemia, an autoimmune condition that attacks the stomach lining and impairs vitamin B12 absorption, has been a suspected link for years, but the pooled data showed no statistically significant association either.¹ That said, some individual clinic studies have found that a meaningful proportion of lichen sclerosus patients carry gastric parietal cell antibodies and low B12 levels, which are precursors to pernicious anemia, leading some clinicians to screen for it regardless.⁹

Conditions That Seem Linked but Probably Are Not

Several autoimmune diseases commonly appear in lists of lichen sclerosus associations but have not held up under rigorous pooled analysis. Systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, and ulcerative colitis all showed no significant association in the 2025 meta-analysis.¹

Type 1 diabetes is a notable case of conflicting evidence. The large German retrospective study found a roughly twofold higher rate in lichen sclerosus patients.⁸ But the meta-analysis, which pooled multiple studies to get a broader picture, did not find the association significant. This kind of discrepancy is common in medical research: a single large study can find a link that disappears when you combine it with other data. The current best evidence leans toward no meaningful connection, but it is worth watching as more data come in.

If you have lichen sclerosus and lupus, or lichen sclerosus and rheumatoid arthritis, the two conditions may still coexist by coincidence, since autoimmune diseases are fairly common overall. The point is that lichen sclerosus does not appear to specifically raise your risk for those particular conditions the way it does for thyroid disease, morphea, or vitiligo.

Why the Autoimmune Link Exists

Lichen sclerosus is increasingly understood as an autoimmune disease itself, not just a disease that happens to travel with autoimmune companions. A key piece of evidence came from the discovery that many lichen sclerosus patients produce autoantibodies against a protein called extracellular matrix protein 1 (ECM1), which helps hold skin together. When researchers injected purified antibodies from lichen sclerosus patients into mice, the animals’ skin developed inflammation, swelling, and blood vessel changes that looked like early lichen sclerosus.¹⁰ Separate work confirmed that circulating antibodies to ECM1 are found specifically in lichen sclerosus and not in healthy controls, offering a plausible mechanism for the tissue damage the disease causes.¹¹

Patients with lichen sclerosus also frequently carry antibodies against basement membrane zone proteins, particularly BP180, the same protein targeted in the blistering skin disease bullous pemphigoid. About a third of vulvar lichen sclerosus patients in one study had these antibodies.¹² Even children with vulvar lichen sclerosus carry BP180 antibodies, suggesting the autoimmune component is present from the earliest stages of disease.¹³ Interestingly, these BP180 antibodies do not seem to track with how severe the itching or scarring is at any given time, which means their presence is better understood as a marker of the autoimmune process rather than a measure of current disease activity.¹⁴

Genetic Susceptibility and Shared Immune Genes

The reason lichen sclerosus clusters with other autoimmune diseases probably has a lot to do with shared genetics. The same family of immune system genes that raise risk for thyroid disease, celiac disease, and vitiligo also raise risk for lichen sclerosus. A genome-wide study identified 14 regions of the genome associated with lichen sclerosus, with the strongest signal coming from a particular immune gene variant, HLA-DRB1*12:01, which roughly doubled the odds of developing the condition in both women and men.¹⁵ Earlier studies had already found that the HLA-DQ7 marker appeared more often in lichen sclerosus patients of both sexes.¹⁶

HLA genes regulate how the immune system identifies threats, and variants in this region are implicated in dozens of autoimmune diseases. If you carry HLA variants that predispose you to one autoimmune condition, you often carry risk for others too. This shared genetic architecture likely explains why lichen sclerosus does not just co-occur with one other autoimmune disease but with a whole cluster of them. Familial studies support this idea: lichen sclerosus runs in families, and affected families tend to have slightly higher rates of other autoimmune diseases as well.¹⁷

What Screening Makes Sense

Given the autoimmune overlap, some specialized clinics have started screening all lichen sclerosus patients for certain conditions as a default. A recent Australian study evaluating screening patterns in a multidisciplinary vulvar unit found high enough rates of thyroid abnormalities, thyroid antibodies, parietal cell antibodies, and low B12 to justify routine bloodwork for thyroid function and pernicious anemia markers.⁹ The authors recommended at minimum a thyroid stimulating hormone (TSH) test for all women with vulvar lichen sclerosus.⁷

This is not yet universal practice. Many dermatologists and gynecologists who manage lichen sclerosus do not routinely order thyroid panels or celiac screens. Whether your doctor suggests these tests may depend on your symptoms, family history, and how your local clinic approaches the condition. If you have lichen sclerosus and are experiencing unexplained fatigue, weight changes, hair thinning, or digestive problems, bringing up autoimmune screening with your doctor is reasonable and well supported by the research.

Microbiome Differences in Lichen Sclerosus

Researchers have recently started exploring whether the microbial communities on the skin and in the gut of lichen sclerosus patients differ from those of healthy people. A case-control study of women with genital lichen sclerosus found a significantly higher abundance of Streptococcus bacteria in both the urinary and vaginal microbiomes compared to controls. Streptococcus has also been found at higher levels in the skin lesions of vitiligo, suggesting a possible broader connection between this bacterial genus and autoimmune skin diseases.¹⁸ The same study found differences in gut bacteria as well, with lichen sclerosus patients carrying higher levels of certain organisms that have also been linked to disease activity in rheumatoid arthritis and multiple sclerosis.

A separate study of perimenopausal and postmenopausal women with vulvar lichen sclerosus found shifts in gut, skin, and vaginal bacterial communities, including higher levels of a bacterium called Parabacteroides, which has been associated with inflammatory immune responses.¹⁹ This research is still early, and no one is suggesting that taking a probiotic will prevent or treat lichen sclerosus. But the microbiome angle reinforces the view that the condition involves immune dysregulation that extends well beyond the affected patch of skin.

Cancer Risk and the Importance of Treatment

The autoimmune and inflammatory nature of lichen sclerosus has implications beyond its associated diseases. Untreated lichen sclerosus is linked to a greater degree of scarring and an elevated risk of squamous cell carcinoma in the genital area.²⁰ A systematic review of the evidence confirmed that women with lichen sclerosus face an increased risk of vulvar squamous cell carcinoma specifically.²¹ The absolute risk remains low for any individual patient, but it is high enough that long-term follow-up is considered essential. Adequate treatment, which typically means regular use of potent topical corticosteroids, appears to reduce both scarring progression and cancer risk, which is why clinicians push for consistent management even when symptoms are mild.

The fact that lichen sclerosus is now firmly placed in the autoimmune category has also opened up discussion about newer treatment approaches. Calcineurin inhibitors and retinoids are sometimes used when corticosteroids fail or are not tolerated.²² And the understanding that chronic inflammation in lichen sclerosus involves specific cytokines has raised interest in whether biologic drugs that target those cytokines, already used in psoriasis and other autoimmune conditions, could help patients with severe disease.

The Mental Health Dimension

Beyond its connections to other autoimmune diseases, lichen sclerosus imposes a substantial burden on mental health that has its own immunological explanation. The persistent inflammatory state in lichen sclerosus produces elevated levels of pro-inflammatory cytokines that can interfere with neurotransmitter metabolism, affecting dopamine, serotonin, and noradrenaline pathways. This mechanism may contribute to the higher rates of depression, anxiety, and other psychiatric conditions seen in lichen sclerosus patients.²³

The financial and quality-of-life costs compound rapidly. An analysis of health plan data found that members with lichen sclerosus had average annual healthcare costs roughly 3.5 times higher than the plan average. When a behavioral health condition was also present, costs climbed to nearly six times the average.²⁴ These numbers underscore something that patients often feel acutely: lichen sclerosus is not “just a skin condition.” The interplay between chronic inflammation, autoimmune comorbidities, and their psychological fallout creates a cycle that demands attention to the whole person, not just the affected tissue.